$COR

DURCAN DERMOT MARK purchased $1.1M of COR

DURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $274.19 ($1.10M total) on 2026-06-18.

Original reporting
SEC EDGAR · DURCAN DERMOT MARK
Published Jun 22, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$COR
Bullish
medium confidence
Mentioned
$COR
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value, post-transaction holdings). This can slightly influence sentiment but does not change fundamentals in the text.

02

Market read

Traders may note the insider buy, but the disclosure alone is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

No context on whether the purchase was part of a broader pattern, compensation-related activity, or personal liquidity needs; also no 10b5-1 plan is stated, but that alone doesn’t confirm conviction.

Relevance 7/10Novelty 5/10Timing: after-hours/filing timestamp (2026-06-22) for a 2026-06-18 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora (COR).

Company-level read

Ticker impact

$CORBullishMedium confidence
Context

Cencora director Durcan Dermot Mark filed a Form 4 open-market purchase of 4,000 shares at $274.19 on 2026-06-18.

Expected impact

Likely limited near-term impact; any effect would be small and fade unless followed by additional disclosures or operational news.

Evidence & confidence

The filing is a routine director open-market purchase (no 10b5-1 plan), but the article provides no new company fundamentals, guidance, or event beyond the transaction details.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Director purchases can be discretionary and may not reflect a new thesis; the disclosed size may be too small to matter for valuation.

Key entities

  • Cencora, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • DURCAN DERMOT MARK

    Director who purchased 4,000 shares of COR open-market on 2026-06-18.

Related articles

$CORMed

The Bull Case For Cencora (COR) Could Change Following Raised EPS Outlook And Bigger Buybacks And Dividend

Cencora (COR) reported Q3 2026 sales of $84.75B and net income of $763.5M, and amended credit and receivables facilities, expanding revolving capacity to $7.0B. The company raised its fiscal 2026 adjusted EPS outlook, completed a $2.0B buyback tranche, and declared a $0.60 quarterly dividend. It flagged a possible earnings headwind tied to an MWI Animal Health-Covetrus merger.

$CORMedAI 8/10

Cencora Q3 Earnings Call Highlights

Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.

$CORMed

Cencora, Inc. Q3 2026 Earnings Call Summary

Cencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.

$CORHigh

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted